Myocardial extracellular volume fraction (ECV) assessed by cardiovascular magnetic resonance (CMR) estimates the extent of the myocardial extracellular space relative to its cellular component (1) . ECV measured by CMR is increased in a variety of diseases(2)(3) and has been validated against histologically derived myocardial ECV (4) . Furthermore, ECV shows promise in prognostication of mortality and morbidity(5) (6) . Conventionally, ECV calculation requires knowledge of the patient's hematocrit (Hct). Treibel et al. (7) recently demonstrated that a 'synthetic ECV' can be calculated by estimating Hct from the longitudinal relaxivity (R1 = 1/T1) of blood. This new approach to ECV estimation eliminates the time, cost and inconvenience associated with obtaining a venous Hct sample. So far, synthetic ECV has only been described for data acquired with a single vendor (Siemens) and field strength (1.5T).
We hypothesised that synthetic ECV can also be derived from data acquired with other platforms and acquisition methods, which would further broaden the applicability of this method.
In this single centre cross-sectional study, we analysed the data of 421 patients who Scar was included within the interventricular septum ROI when present. Analysis was blinded. Statistical analyses were performed using SPSS version 22 (Chicago, Illinois). All results are presented as mean ± standard deviation.
There was a broad range of Hct in both 1.5T and 3.0T derivation groups (0.41 ± 0.05, range 0.27 to 0.53 at 1.5T and 0.42 ± 0.04, range 0.31 to 0.54 at 3.0T). There was also a broad range of blood T1 in 1.5T and 3.0T derivation groups (1608 ± 105 ms, range 1402 to 1912 ms at 1.5T and 1780 ± 99ms, range 1457 to 1993 ms at 3.0T).
The conventionally calculated ECV in the validation groups was 32 ± 9 % (range 19 to 77%) for 1.5T and 29 ± 5 % (range 20 to 53%) for 3.0T.
The regression lines between Hct and R1 blood were linear at both field strengths 
